“IgG4相关疾病”得到明确——它让一些“癌症病人”得到昭雪

2017-10-09 杨岫岩 杨氏书屋

医学无止境,不时会有一些非常疑难的疾病展现在医生面前。难到什么程度?“无名氏”疾病!医生没有办法下诊断,“喊”不出其名字,是因为这个疾病还没有被命名。

作者:中山大学附属第一医院风湿免疫科  杨岫岩医学无止境,不时会有一些非常疑难的疾病展现在医生面前。难到什么程度?“无名氏”疾病!医生没有办法下诊断,“喊”不出其名字,是因为这个疾病还没有被命名。“无名氏”疾病终于有名字2016年2月,医学界最重要的期刊《新英格兰医学杂志》发表了一篇题为“IgG4相关疾病”的文章,使一类非常疑难的“无名氏”疾病获得了统一的命名。   虽然“IgG4相关疾病”是21世纪才被认识的“新”疾病,但实际上它是在人类历史上长期存在且临床上并不罕见的一类疾病。上个世纪末,人体免疫球蛋白IgG的各个亚型进入了研究者们的视线。   最早关注到IgG4的是消化科的专家们。2000年左右,他们发现有一种自身免疫性胰腺炎与IgG的一个亚型IgG4密切相关。这种胰腺炎表现为胰腺肿大,超声波和CT或MRI常常诊断为胰腺癌,但是病理活检却找不到癌细胞。数年后,各个学科的医生们也陆续发现,各种组织和脏器的肿胀、炎症、纤维化等改变与IgG4有关系。由于损害的部位不同,临床表现差异很大,但有一个共同的特点,就是血液中的IgG4增高,病理

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1482965, encodeId=c637148296585, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598944, encodeId=8d9c15989447e, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615181, encodeId=e57e161518118, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251568, encodeId=58e325156877, content=学习.这段时间老师也在讲这个, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/be4YlKNv3rT6se8HUMWmAyS3eywXjKkf3TaeJkKrgAdTM1l1WesYwgkw2VAOVEWicdb6rCiaRbttqjb9ozpjCkGQ/0, createdBy=2d322139779, createdName=欧阳星月dora, createdTime=Mon Oct 09 20:00:47 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251563, encodeId=59b2251563dd, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Oct 09 19:40:29 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1482965, encodeId=c637148296585, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598944, encodeId=8d9c15989447e, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615181, encodeId=e57e161518118, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251568, encodeId=58e325156877, content=学习.这段时间老师也在讲这个, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/be4YlKNv3rT6se8HUMWmAyS3eywXjKkf3TaeJkKrgAdTM1l1WesYwgkw2VAOVEWicdb6rCiaRbttqjb9ozpjCkGQ/0, createdBy=2d322139779, createdName=欧阳星月dora, createdTime=Mon Oct 09 20:00:47 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251563, encodeId=59b2251563dd, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Oct 09 19:40:29 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1482965, encodeId=c637148296585, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598944, encodeId=8d9c15989447e, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615181, encodeId=e57e161518118, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251568, encodeId=58e325156877, content=学习.这段时间老师也在讲这个, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/be4YlKNv3rT6se8HUMWmAyS3eywXjKkf3TaeJkKrgAdTM1l1WesYwgkw2VAOVEWicdb6rCiaRbttqjb9ozpjCkGQ/0, createdBy=2d322139779, createdName=欧阳星月dora, createdTime=Mon Oct 09 20:00:47 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251563, encodeId=59b2251563dd, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Oct 09 19:40:29 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1482965, encodeId=c637148296585, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598944, encodeId=8d9c15989447e, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615181, encodeId=e57e161518118, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251568, encodeId=58e325156877, content=学习.这段时间老师也在讲这个, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/be4YlKNv3rT6se8HUMWmAyS3eywXjKkf3TaeJkKrgAdTM1l1WesYwgkw2VAOVEWicdb6rCiaRbttqjb9ozpjCkGQ/0, createdBy=2d322139779, createdName=欧阳星月dora, createdTime=Mon Oct 09 20:00:47 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251563, encodeId=59b2251563dd, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Oct 09 19:40:29 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
    2017-10-09 欧阳星月dora

    学习.这段时间老师也在讲这个

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1482965, encodeId=c637148296585, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598944, encodeId=8d9c15989447e, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615181, encodeId=e57e161518118, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Wed Oct 11 07:27:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251568, encodeId=58e325156877, content=学习.这段时间老师也在讲这个, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/be4YlKNv3rT6se8HUMWmAyS3eywXjKkf3TaeJkKrgAdTM1l1WesYwgkw2VAOVEWicdb6rCiaRbttqjb9ozpjCkGQ/0, createdBy=2d322139779, createdName=欧阳星月dora, createdTime=Mon Oct 09 20:00:47 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251563, encodeId=59b2251563dd, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Oct 09 19:40:29 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
    2017-10-09 137****9095

    henhao

    0

相关资讯

解读《IgG4相关性疾病管理和治疗的国际共识指南》

2015年3月,Arthritis&Rheumatology杂志发表了《IgG4相关性疾病管理和治疗的国际共识指南》,以下简称指南。该指南是迄今为止国际上关于IgG4相关性疾病(IgG4-relateddisease,IgG4-RD)诊治和管理的首个指导性意见,对指导IgG4-RD的临床实践有重要意义。 指南制定背景 IgG4-RD是一种免疫介导的炎症伴纤维化疾病,可影响多个器官,